17,261 trials
RSV Infection
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious AEs (TESAEs), AEs of Special Interest (AESIs), and New Onset Chronic…
Colonoscopy
Primary: Number and Percentage of Subjects With Successful Bowel Cleansing — 35; 36; 16; 19 Participants
Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
Primary: Intraepidermal Nerve Fiber Density (IENFD) — -0.6064; -0.396 fibers/mm/year (52 weeks)
Dry Eye Disease
Primary: Number of Subjects With At Least One (1) Treatment Emergent Adverse Event — 0; 16; 15; 5 count of participants
BH4 Deficiency · Hyperphenylalaninemia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 2; 2; 4; 3 Participants
Glioblastoma · Malignant Glioma
Primary: Overall Survival (OS) — 0.54 proportion of successes
Small Bowel Cancers · Colorectal Cancers
Primary: Objective Response Rate (ORR) for Triple Therapy — 0; 0 Proportion of participants
Urinary Tract Infections
Primary: Number of Participant With Urinary Tract Infection — 12; 13 Participants
Abdominal Aortic Aneurysm
Primary: Annual Aneurysm Growth Rate Between Patients With and Without Micro Bubble Uptake — 3.0; 3.2 mm/year
POEMS Syndrome
Primary: Treatment Success — 0 Participants
Kidney Cancer
Primary: 3D CEUS Generated Metrics in Kidney Mass: Wash_In_Slope — 7.60 AU/second
Marginal Zone Lymphoma · Follicular Lymphoma
Primary: Number of Participants With Complete Response Rate (CR) at 8 Weeks Post Single Agent Induction — 2 Participants
Treatment Resistant Depression
Primary: Improvement in Depressive Symptoms — -14.9 units on a scale
Type2 Diabetes
Primary: Fasting Glucose Measured Using Continuous Glucose Monitoring — 148.6; 142.1 mg/dL
Soft Tissue Sarcoma
Primary: Change in Total T-cell Level in Tumour Tissues From Baseline (Step 1, Week 1, Day 1) to End of Step 1 (Step 1, Week 3-5) — 1.9 factor change in cells/mm2